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INTRODUCTION
Chronic spontaneous urticaria (CSU), a subtype of chronic 
urticaria (CU), is defined as episodes of recurrent spontaneous 
wheals and/or angioedema lasting more than 6 weeks.1 A pop-
ulation-based study of Korea reported that the crude preva-
lence of CU was 2,256.5 per 100,000 person-years and tended 
to increase every year between 2010 and 2014.2 Hospital-based 
study of Korea showed that the prevalence of CU in children is 
1.8%, which appears to be similar to that in adults.3 CSU im-
pairs quality of life by affecting many aspects of quality of life, 
such as sleep and daily activities, and has considerable human-
istic and economic impacts.4,5
Second-generation antihistamines are the first-line agents for 
the treatment of CSU, and omalizumab (Xolair®; Genentech, 
Inc., South San Francisco, CA, USA) 300 mg/month is recom-
mended for antihistamine refractory patients in whom high-
dose antihistamines fail to control symptoms. Cyclosporin 
(Sandimmune®; Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA) is recommended for patients who are unre-
sponsive to both antihistamines and omalizuamb.6 Although 
knowledge of the clinical course of CSU is important clinically 
for determining patient prognosis and assessing its social and 
economic burden, it remains unclear. The purpose of our study 
was to investigate the clinical course of CSU in the Korean adult 
population using insurance claim data. To our knowledge, this 
is the first study on the clinical course of CSU using a nation-
wide database.
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MATERIALS AND METHODS
This is a population-based study using the Korean National 
Health Insurance Service National Sample Cohort (NHIS-NSC) 
2002-2013 from the Korean National Health Insurance Service 
(KNHIS). This database is composed of approximately 1 mil-
lion nationally representative random subjects and includes all 
medical claims from 2002 to 2013, and details of database is 
previously described.7 The KNHIS uses International Classifica-
tion of Disease, Tenth Revision, Clinical Modification codes.
We used the same definition of CSU as a previous report from 
our group.8 This definition was validated to have a positive pre-
dictive value of 90.4% and a sensitivity of 71.1%.9 We made the 
CSU group who fulfilled 1 of the 2 criteria in a year between 
2003 and 2007 as previously described.8 We excluded subjects 
under the age of 20. Also, we excluded subjects diagnosed with 
CSU in 2002 to ensure that the CSU group only included sub-
jects with new episodes. Each patient in the CSU group was 
tracked whether he or she went into remission or not until 
2013. We defined remission as not being diagnosed with urti-
caria (L50.1, L50.8, or L50.9) for at least 1 year during follow-up. 
The last date of CSU diagnosis was defined as the date of remis-
sion. Subjects who were no longer available to be followed up 
due to their death during the study periods were excluded for 
the survival analysis.
All data are displayed as the number of subjects plus the per-
centage in each group for categorical variables. Kaplan-Meier 
survival analysis was carried out to analyze the remission rate, 
and log-rank tests were performed for between-group compar-
isons. Demographic differences between subjects who went 
into remission 1 year after the initial diagnosis and those who 
did not were analyzed using χ2 tests, and P<0.05 was consid-
ered statistically significant. To further estimate differences in 
gender between individual age groups, we calculated odds ra-
tios (ORs) and 95% confidence intervals (CIs).
RESULTS
A total of 13,969 subjects included between 2003 and 2007 
were followed up during a median period of 2,471 days. Medi-
an disease duration in subjects who underwent remission in 
the study period was 392 days. Among them, 8,626 (61.75%) 
were female and 5,343 (38.25%) were male. The proportion of 
subjects in the 20-39, 40-64, and 65+ age groups were 30.63%, 
49.69%, and 19.68%, respectively.
Table displays the basic characteristics of the study popula-
tion and demographic differences between subjects who went 
into remission 1 year after the initial diagnosis and those who 
did not. The proportion of subjects in the 65+ age group (P=  
0.050) and with male gender (P=0.002) was significantly higher 
among subjects who did not go into remission 1 year after the 
initial diagnosis compared to those who did. Subjects aged 65+ 
showed a significant negative association with 1-year remission 
state compared to those aged 20-39 (OR, 0.86; 95% CI, 0.77-
0.97). Female subjects showed a significant positive association 
with 1-year remission state compared to male subjects (OR, 
1.15; 95% CI, 1.53-1.25).
Figure displays the Kaplan-Meier survival analysis of persis-
tence of CSU in the study groups, and between-group analysis. 
The 1-, 2-, 3-, 4-, and 5-year remission rates of CSU were 21.5%, 
33.0%, 38.9%, 42.6%, and 44.6%, respectively. Between-group 
analysis using the log-rank test showed that there were signifi-
cant differences in the remission rates of CSU between the 20-
64 and 65+ age groups (P=0.040) and between males and fe-
males (P<0.001).
DISCUSSION
We found that the 1-, 2-, and 5-year remission rates of CSU 
were 21.5%, 33.0%, and 44.6%, respectively. The clinical course 
of CSU is unpredictable, and remission rates were variously re-
ported.10 Kozel et al.11 and Kulthanan et al.12 reported that 
Table. Basic characteristics of the study population and demographic differences between subjects who went into remission 1 year after the initial diagnosis and 
those who did not
Variable Overall subjects Remission after 1 year (%) OR (95% CI) for 1 year remission No remission after 1 year (%) P value*
Total No. 13,969 3,009 (21.54) 10,960 (78.46)
Gender 0.002
   Male 5,343 1,076 (20.14) 1.00 (reference) 4,267 (79.86)
   Female 8,626 1,933 (22.41) 1.15 (1.05-1.25) 6,693 (77.59)
Age at initial diagnosis (year) 0.050
   20-39 4,279 963 (22.51) 1.00 (reference) 3,316 (77.49)
   40-64 6,941 1,495 (21.54) 0.95 (0.86-1.04) 5,446 (78.46)
   65+ 2,749 551 (20.04) 0.86 (0.77-0.97) 2,198 (79.96)
OR, odds ratio; CI, confidence interval.
*The P value was calculated by comparing subjects who went into remission 1 year after the initial diagnosis and those who did not, using χ2 tests.
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1-year remission rates of CSU were 35% and 34.5%, respective-
ly. Van der valk et al.13 reported that 5- and 10-year remission 
rates of CSU were 29% and 44%, respectively. Hiragun et al.14 re-
ported that 1-, 2-, and 5-year remission rates of CSU were 
11.5%, 13.9%, and 27.7%, respectively, and Toubi et al.15 report-
ed that 1-, 2-, and 5-year remission rates of CSU were 25%, 48%, 
and 86%, respectively. The 1-, 2-, and 5-year remission rates 
found in our study were lower than those in previous studies 
except for a study by Hiragun et al.14 Their study only included 
subjects with CSU that was not controlled by a standard dose of 
antihistamine, which might contribute to the lowest remission 
rate. In Korea, Ye et al.10 reported that the 6-month remission 
rate of CSU was 3.4% after treatment according to the guideline. 
Although remission rate after 6 months was not studied in their 
Figure. Kaplan-Meier survival analysis for the remission of CSU in the whole study group, and between-group analysis for gender and age. (A) The whole study 
group. (B) The male and female groups, (C) The 20-64 and 65+ age groups. CSU, chronic spontaneous urticaria.
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study, remission rates were lower than ours. In their study, the 
study population driven from 3 referral hospitals and relatively 
strict definition of remission might have contributed to these 
results.
Previous studies had weaknesses, such as a small sample size 
with a hospital-based design. Also, they were heterogeneous in 
terms of the study population, inclusion criteria of CSU, treat-
ment methodology, and definition of remission. Our popula-
tion-based nationwide study included Korean subjects with 
CSU, which was defined using disease codes. Not all subjects in 
our study were treated according to the recent guidelines.1 A 
multicenter study in Germany found that the majority of CSU 
subjects were undertreated, had uncontrolled urticaria.16 Like-
wise, subjects with CSU in our study might be undertreated in 
real-world practice. Omalizumab has been well demonstrated 
to safely and effectively control CSU at least partially in approxi-
mately 2/3 of cases.17 In Korea, omalizumab was not approved 
for the treatment CSU in the study period, which could have 
contributed to lower remission rate. Because this is an observa-
tional study, not an interventional study, it is hard to evaluate to 
the effect of treatment modalities on the prognosis of CSU. The 
definition of remission used in our study was relatively strict. 
We speculate that these reasons might influence the lower re-
mission rates found in our study.
In this study, an age of 65+ and male gender were poor prog-
nostic factors affecting the remission rate. However, previous 
studies reported that age or gender did not affect the clinical 
course of CSU in the adult population.10,14,18 On the other hand, 
angioedema, severe CSU, antithyroid antibodies, and/or posi-
tive autologous serum skin test findings have been reported to 
be poor prognostic factors for CSU.10,14,15
This study has some limitations. First, the diagnosis of CSU 
was defined on the basis of disease codes. Subjects with de-
fined CSU in our study had a possibility that they did not be di-
agnosed with CSU in real-world practice. Furthermore, medi-
cal visit does not assure active urticarial symptoms. Secondly, 
information on use of over-the-counter medications was un-
available. Thirdly, because the remission rate was defined by 
disease codes, remission state might have been interpreted as 
the condition not requiring medical intervention. Also, recur-
rence of CSU might occur after the defined remission state. 
Fourthly, right censoring that some patients did not undergo 
remission state at the end of the study should be considered in 
the interpretation of the results. However, as this database con-
tained data from 2002 to 2013, each patient was followed up for 
at least 6 years, which could have contributed to the value of 
our results. Despite these limitations, our nationwide study in-
cluded a large number of subjects from the primary care clinics 
to the referral hospitals. 
In summary, our population-based, nationwide study dem-
onstrated that the 1-, 2-, and 5-year remission rates of CSU in 
the Korean adult population were 21.5%, 33.0%, and 44.6%, re-
spectively. An age of 65+ and male gender were found to be 
poor prognostic factors for CSU. These results indicate that CSU 
may have a more persistent course than previously reported.
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